Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report
Authors:
Open Access
- 9 March 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1051786
Abstract
Primary colon squamous cell carcinoma (SCC) is extremely rare and associated with a poor prognosis. Moreover, there is no treatment guideline for this disease. Proficient mismatch repair/microsatellite-stable (pMMR/MSS) colorectal adenocarcinoma is refractory to immune monotherapy. Although the combination of immunotherapy with chemotherapy in pMMR/MSS colorectal cancer (CRC) is currently under investigation, the clinical activity of this approach in colorectal SCC remains unknown. In this article, we report the case of a pMMR/MSS CRC patient with ascending colon SCC who had high programmed cell death–ligand 1 (PD-L1) expression and the a missense mutation in codon 600 of the B-Raf proto-oncogene (BRAF V600E) mutation. The patient exhibited a significant response to the combination of immunotherapy and chemotherapy. After eight cycles of treatment with the combination of sintilimab and mFOLFOX6 (oxaliplatin, fluorouracil, and leucovorin), computed tomography–guided microwave ablation of the liver metastasis was performed. The patient achieved excellent durable response and continues to experience a good quality of life. The present case indicates that programmed cell death 1 blockade combined with chemotherapy may be an effective therapy for patients with pMMR/MSS colon SCC and high PD-L1 expression. Furthermore, PD-L1 expression may be a biomarker for immunotherapy in patients with colorectal SCC.Keywords
This publication has 11 references indexed in Scilit:
- Rectosigmoid-Junction Squamous Cell Carcinoma With pMMR/MSS Achieved a Partial Response Following PD-1 Blockade Combined With Chemotherapy: A Case ReportFrontiers in Oncology, 2021
- Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAFV600E Mutation Showed a Complete Metabolic Response to PD-1 Blockade and Bevacizumab: A Case ReportFrontiers in Oncology, 2021
- Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?Frontiers in Immunology, 2019
- Anticancer Research2018
- Squamous Cell Carcinoma of Colon—an Etiopathological SurpriseJournal of Gastrointestinal Cancer, 2018
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinomaPLOS ONE, 2017
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade TherapyImmunity, 2016
- Squamous Cell Carcinoma of the Colon with an Elevated Serum Squamous Cell Carcinoma Antigen Responding to Combination ChemotherapyClinical Colorectal Cancer, 2001
- Adenosquamous and squamous carcinoma of the colon and upper rectumDiseases of the Colon & Rectum, 2001
- Squamous-cell carcinoma of the colon responsive to combination chemotherapyDiseases of the Colon & Rectum, 1999